Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 54466-54468 [2021-21402]
Download as PDF
<![CDATA[
54466
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Notices
Dated: September 28, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21396 Filed 9–30–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Refugee Resettlement
Public/Private Refugee Cash
Assistance Inflationary Increase
Office of Refugee Resettlement
(ORR), Administration for Children and
Families (ACF), Department of Health
and Human Services (HHS).
ACTION: Notice of change in payment
ceilings.
AGENCY:
In accordance with ORR
regulations, the Director of ORR is
announcing an inflationary increase to
the public/private Refugee Cash
Assistance (RCA) program’s monthly
payment ceilings, effective October 1,
2021. The current payment ceilings
have remained fixed since March 22,
2000, despite inflation. The new
payment ceilings accommodate that
inflation and will provide arriving ORReligible populations greater economic
stability as they transition to selfsufficiency.
SUMMARY:
The changes described in this
Federal Register Notice are effective
October 1, 2021.
FOR FURTHER INFORMATION CONTACT:
Colleen Mahar-Piersma, Refugee Policy
Unit, Division of Policy and Procedures,
Office of the Director, Office of Refugee
Resettlement, Administration for
Children and Families, by phone at
(202) 260–5493, and email at
refugeepolicy@acf.hhs.gov.
SUPPLEMENTARY INFORMATION:
ORR-eligible populations are eligible
for up to eight months of RCA after their
initial ORR eligibility date if they are
deemed ineligible for the Temporary
Assistance for Needy Families (TANF)
program. When TANF was established
in 1996, ORR gave states the option to
either establish a publicly administered
RCA program modeled after their TANF
program in terms of eligibility
determinations and benefits levels, or
the option to establish a public/private
partnership (PPP) RCA program. States
that chose the PPP RCA model proposed
a plan to ORR that created their income
eligibility standard and may have
included sliding scale payments or
incentives for early employment aimed
at refugee self-sufficiency, as long as
DATES:
VerDate Sep<11>2014
18:04 Sep 30, 2021
Jkt 256001
they remained within the established
payment ceilings.
ORR established the PPP RCA
monthly payment ceilings codified at 45
CFR 400.60(a) using the poverty
guidelines developed by the Assistant
Secretary for Planning and Evaluation
within HHS. These poverty guidelines,
which are updated annually, are mainly
used for administrative purposes such
as determining an individual’s
eligibility for certain programs. When
ORR established the current PPP RCA
monthly payment ceilings, it used the
1998 HHS Poverty Guidelines with the
following formula: ‘‘50% of the 1998
HHS Poverty Guidelines for each family
size, divided by 12 months. . . .’’
Where family units were greater than
four people, the monthly payment
ceiling was increased by $70 for each
additional person.
These PPP RCA payment ceilings
have remained fixed since March 22,
2000, despite inflation and an increased
cost of living nationwide. The payment
ceilings are insufficient to meet
refugees’ initial expenses for housing,
utilities, transportation, food, and other
essentials, as they acclimate to their
new communities and try to secure
employment. Refugees generally have
no other means of assistance such as
savings or family resources to assist in
the early days of arrival. Additionally,
more than half of current projected
ORR-eligible arrivals do not benefit from
assistance from the Department of
State’s Reception and Placement
Program, making RCA a critical source
of support as they strive for economic
self-sufficiency and integration.
As such, in accordance with ORR
regulations at 45 CFR 400.60(d), the
ORR Director has determined that the
PPP RCA payment ceilings need to be
adjusted for inflation.
Using ORR’s original formula in
relation to the 2021 HHS poverty
guidelines, the adjusted PPP RCA
payment ceilings are:
administered programs. All remaining
RCA programs must continue to follow
their established TANF rate.
To implement the RCA payment
ceilings outlined in this Notice, the
State/Replacement Designee (RD) must
first revise its State Plan and ORR–1
CMA estimate. ORR will issue further
guidance on how a State/RD should
address implementation of the new
public/private partnership RCA rate in
its State Plan and ORR–1 prior to the
implementation of the increased rate.
ORR will also conduct minimally, a
bi-annual review of the HHS Poverty
Guidelines, the established PPP rates,
and the availability of funding with the
goal of enacting more responsive and
equitable cash assistance rates in the
public/private RCA program.
(Authority: 45 CFR 400.60)
Dated: September 24, 2021.
Cindy Huang,
Director of the Office of Refugee Resettlement.
[FR Doc. 2021–21369 Filed 9–30–21; 8:45 am]
BILLING CODE 4120–27–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
PUBLIC/PRIVATE RCA PAYMENT
Programs using Urine or Oral Fluid
CEILINGS
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Monthly
Anastasia Donovan, Division of
Size of family unit
payment
ceiling
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
1 ............................................
$537 Rockville, Maryland 20857; 240–276–
2 ............................................
726
2600 (voice); Anastasia.Donovan@
3 ............................................
915
4 ............................................
1,104 samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Where family units are greater than
Mandatory Guidelines, a notice listing
four people, the monthly payment
all currently HHS-certified laboratories
ceiling is increased by $113 for each
and IITFs is published in the Federal
additional person.
These payment ceilings only apply to Register during the first week of each
RCA recipients within PPPmonth. If any laboratory or IITF
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
SUMMARY:
E:\FR\FM\01OCN1.SGM
01OCN1
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Notices
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
VerDate Sep<11>2014
18:04 Sep 30, 2021
Jkt 256001
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid dated
October 25, 2019 (84 FR 57554), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified IITFs meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190 (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
To Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified laboratories meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823 (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130 (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Cordant Health Solutions, 2617 East L
Street, Tacoma, WA 98421, 800–442–
0438 (Formerly: STERLING Reference
Laboratories)
Desert Tox, LLC, 5425 E Bell Rd, Suite
125, Scottsdale, AZ 85254, 602–457–
5411/623–748–5045
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
54467
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
Dynacare,* 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630 (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339 (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Legacy Laboratory Services Toxicology,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
MedTox Laboratories, Inc., 402 W
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088. Testing for Veterans Affairs
(VA) Employees Only
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
E:\FR\FM\01OCN1.SGM
01OCN1
54468
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Notices
Clinical Laboratories; SmithKline BioScience Laboratories)
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only
The following laboratory voluntarily
withdrew from the National Laboratory
Certification Program effective
September 3, 2021:
Redwood Toxicology Laboratory, 3700
Westwind Blvd., Santa Rosa, CA
95403, 800–255–2159
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on January 23, 2017 (82 FR
7920). After receiving DOT certification,
the laboratory will be included in the
monthly list of HHS-certified
laboratories and participate in the NLCP
certification maintenance program.
Anastasia Marie Donovan,
Policy Analyst, Division of Workplace
Programs.
[FR Doc. 2021–21402 Filed 9–30–21; 8:45 am]
BILLING CODE 4160–20–P
VerDate Sep<11>2014
18:04 Sep 30, 2021
Jkt 256001
DEPARTMENT OF THE INTERIOR
Geological Survey
[GX21BD239AV0100; OMB Control Number
1028–NEW]
Agency Information Collection
Activities; Information Collection
Through Surveys and Interviews To
Evaluate and Improve the Cooperative
Research Units Program Mission,
Functions, and Goals
U.S. Geological Survey,
Interior.
ACTION: Notice of information collection;
request for comment.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995, we,
the U.S. Geological Survey (USGS) are
proposing a new information collection.
DATES: Interested persons are invited to
submit comments on or before
November 30, 2021.
ADDRESSES: Send your comments on
this information collection request (ICR)
by mail to U.S. Geological Survey,
Information Collections Officer, 12201
Sunrise Valley Drive MS 159, Reston,
VA 20192; or by email to gs-info_
collections@usgs.gov. Please reference
OMB Control Number 1028–NEW in the
subject line of your comments.
FOR FURTHER INFORMATION CONTACT: To
request additional information about
this ICR, contact Cynthia S. Loftin by
email at cyndy_loftin@usgs.gov, or by
telephone at (207) 581–2843.
Individuals who are hearing or speech
impaired may call the Federal Relay
Service at 1–800–877–8339 for TTY
assistance.
SUMMARY:
In
accordance with the Paperwork
Reduction Act of 1995, we provide the
general public and other Federal
agencies with an opportunity to
comment on new, proposed, revised,
and continuing collections of
information. This helps us assess the
impact of our information collection
requirements and minimize the public’s
reporting burden. It also helps the
public understand our information
collection requirements and provide the
requested data in the desired format.
We are soliciting comments on the
proposed ICR that is described below.
We are especially interested in public
comment addressing the following
issues: (1) Is the collection necessary to
the proper functions of the USGS; (2)
will this information be processed and
used in a timely manner; (3) is the
estimate of burden accurate; (4) how
might the USGS enhance the quality,
utility, and clarity of the information to
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
be collected; and (5) how might the
USGS minimize the burden of this
collection on the respondents, including
through the use of information
technology.
Comments that you submit in
response to this notice are a matter of
public record. We will include or
summarize each comment in our request
to OMB to approve this ICR. Before
including your address, phone number,
email address, or other personal
identifying information in your
comment, you should be aware that
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so.
Abstract: The USGS Cooperative Fish
and Wildlife Research Units Program
originated in 1935 to fill a need for
qualified wildlife and fisheries
professionals and provide evidence
based graduate research to inform
resource management. Currently the
program has 40 individual Units in 38
states and formalizes relationships
among a state natural resources
management agency, a host university,
the USGS, the USFWS, and the Wildlife
Management Institute. The program’s
graduate education and research
mission has remained largely
unchanged through its tenure, yet the
issues challenging fish and wildlife
conservation have transformed. This
raises questions about the program’s
support and sustainability into the
future and how best to address
cooperator needs.
Through focused surveys and
interviews, this information collection
will ask participants to evaluate their
communication and relationships with
individuals in the program. The data
will be used to examine the structure,
communication, and socio-technical
connectivity using network analysis and
agent based modeling. This information
collection aims to improve our
understanding of the Cooperative
Research Units Program and how it
meets its partners’ needs.
Title of Collection: Information
collection through surveys and
interviews to improve the Cooperative
Research Units Program mission,
functions, and goals.
OMB Control Number: 1028–NEW.
Form Number: None.
Type of Review: New.
Respondents/Affected Public:
Universities, state and tribal
governments, and businesses which are
direct (both formal and informal)
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 86, Number 188 (Friday, October 1, 2021)]
[Notices]
[Pages 54466-54468]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21402]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs using
Urine or Oral Fluid (Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT: Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-2600 (voice);
[email protected] (email).
SUPPLEMENTARY INFORMATION: In accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing all currently HHS-certified
laboratories and IITFs is published in the Federal Register during the
first week of each month. If any laboratory or IITF
[[Page 54467]]
certification is suspended or revoked, the laboratory or IITF will be
omitted from subsequent lists until such time as it is restored to full
certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/resources/drug-testing/certified-lab-list.
The Department of Health and Human Services (HHS) notifies federal
agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and of the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020.
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid dated
October 25, 2019 (84 FR 57554), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved To
Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine dated
January 23, 2017 (82 FR 7920), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190 (Formerly: Gamma-Dynacare Medical Laboratories)
HHS-Certified Laboratories Approved To Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine dated
January 23, 2017 (82 FR 7920), the following HHS-certified laboratories
meet the minimum standards to conduct drug and specimen validity tests
on urine specimens:
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917
Cordant Health Solutions, 2617 East L Street, Tacoma, WA 98421, 800-
442-0438 (Formerly: STERLING Reference Laboratories)
Desert Tox, LLC, 5425 E Bell Rd, Suite 125, Scottsdale, AZ 85254, 602-
457-5411/623-748-5045
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
Dynacare,* 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630 (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
Laboratory Corporation of America Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Legacy Laboratory Services Toxicology, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216 (Formerly: SmithKline Beecham
[[Page 54468]]
Clinical Laboratories; SmithKline Bio-Science Laboratories)
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for
Department of Defense (DoD) Employees Only
The following laboratory voluntarily withdrew from the National
Laboratory Certification Program effective September 3, 2021:
Redwood Toxicology Laboratory, 3700 Westwind Blvd., Santa Rosa, CA
95403, 800-255-2159
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on January 23, 2017 (82 FR 7920).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Anastasia Marie Donovan,
Policy Analyst, Division of Workplace Programs.
[FR Doc. 2021-21402 Filed 9-30-21; 8:45 am]
BILLING CODE 4160-20-P
